MP
Insider
Mpm Bioventures 2018, L.P.
10% ownerMpm Bioventures 2018, L.P. (10% owner) filed 5 Form 4 reports as a reporting entity in the trailing twelve months (1 purchase, 4 sales), most often in Entrada Therapeutics, Inc. (TRDA). Across 1 priced purchase filing, the average 21-session return was -20.7% from execution and -15.6% from disclosure (delay-adjusted; derived). The largest single filing was $20.0M of AKTS (1,112,777 sh × $18.00, as filed), executed Jan 12.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
-20.7%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
-15.6%
same 1 filings, from disclosure
Filings, ttm
5
1 buys · 4 sells
Median delay
2d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$23.6M
shares × price, as filed
Last traded
Sep 9
Filed Sep 9
Median ADV $2.8M across their filed names
Open performance→Volume by month
Buys $20.0M
Sells $3.6M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
5 filings
Sector per market data · by filing · past 12 months
Most traded names
TRDARecent filings
TRDASALE
Entrada Therapeutics, Inc.
View filing →
$1.9M259,837 sh across 3 lots
Exec Sep 4
Filed Sep 9 · 7:24 PM ET TRDASALE Entrada Therapeutics, Inc. View filing → $617K
86,482 sh across 3 lots
Exec Sep 1
Filed Sep 3 · 7:21 PM ET TRDASALE Entrada Therapeutics, Inc. View filing → $590K
83,181 sh across 2 lots
Exec Aug 27
Filed Aug 31 · 6:26 PM ET TRDASALE Entrada Therapeutics, Inc. View filing → $462K
62,714 sh across 3 lots
Exec Aug 24
Filed Aug 26 · 9:27 PM ET AKTSPURCHASE Aktis Oncology, Inc. View filing → $20.0M
1,112,777 sh × $18.00
Exec Jan 12
Filed Jan 14 · 6:19 PM ET